Diabetic foot

Kane Biotech Announces Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Tuesday, March 26, 2024
Diabetic foot, Financial statement, PIN, Ulcer, Symposium, Sale, KNE, Pivot, Credit, Leg, SAWC, US FDA, Patent, FDA, Government, Food

WINNIPEG, Manitoba, March 26, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”) today announces its fourth quarter and full year 2023 financial results.

Key Points: 
  • WINNIPEG, Manitoba, March 26, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”) today announces its fourth quarter and full year 2023 financial results.
  • On December 20, 2023, Kane Biotech announced that it received a non-binding offer for its interest in STEM Animal Health.
  • Gross profit for the fourth quarter of 2023 was $398,234, an increase of 24% compared to $320,653 for the fourth quarter ended December 31, 2022.
  • Loss for the fourth quarter of 2023 was ($1,611,894), an increase of 92% compared to ($838,150) for the quarter ended December 31, 2022.

Microbion's Topical Pravibismane Phase 1b Moderate or Severe Diabetic Foot Ulcer Infection Study is Published in International Wound Journal

Retrieved on: 
Thursday, April 4, 2024
DFI, Diabetes, Sepsis, Infection, Incidence, Risk, Ulcer, Patient, Mortality, Adjunct (grammar), University of Washington, University, Manuscript, Standard of care, Quality of life, Diabetic foot, Skin, Safety, Political moderate, Amputation, Medicine, Biofilm, Pharmaceutical industry

and VANCOUVER, BC, April 4, 2024 /PRNewswire/ - Microbion Corporation today announced that the company has published results from its topical pravibismane Phase 1b study in the peer-reviewed International Wound Journal.

Key Points: 
  • and VANCOUVER, BC, April 4, 2024 /PRNewswire/ - Microbion Corporation today announced that the company has published results from its topical pravibismane Phase 1b study in the peer-reviewed International Wound Journal.
  • The manuscript titled "Topical Pravibismane as Adjunctive Therapy for Moderate or Severe Diabetic Foot Infections: A Phase 1b Randomized, Multi-Center, Double-Blind, Placebo-Controlled Trial" is available for free download at International Wound Journal's website ( https://doi.org/10.1111/iwj.14817 ).
  • This therapeutic objective is currently being assessed in our recently completed, 12-week Phase 2 study in moderately infected, chronic diabetic foot ulcers."
  • The published manuscript describes in detail the Phase 1b study that was designed to evaluate the safety and efficacy of pravibismane in managing moderate or severe chronic diabetic foot ulcer infections.

How Cinesteam® Helps Manage Smells From Diabetic Foot

Retrieved on: 
Thursday, February 29, 2024
Diabetes, Smell, Blood, Diabetic foot, Sensation, Pain, Infection, Foot, Diabetic neuropathy, Ulcer, Blister, Mayo Clinic, Peripheral neuropathy, Hypoesthesia, Business, Code, Dentistry

FORT LAUDERDALE, Fla., Feb. 29, 2024 /PRNewswire/ -- Diabetic foot is a common concern for those with diabetes. The condition can lead to chronic wounds that produce highly unpleasant smells. Cinesteam® is a natural-based secondary dressing designed to simply and effectively manage smells like those that come from diabetic foot.

Key Points: 
  • FORT LAUDERDALE, Fla., Feb. 29, 2024 /PRNewswire/ -- Diabetic foot is a common concern for those with diabetes.
  • Cinesteam® is a natural-based secondary dressing designed to simply and effectively manage smells like those that come from diabetic foot.
  • The medical condition comes with many health concerns, one of which is commonly referred to as "diabetic foot."
  • Mayo Clinic reports that as much as 50% of those with diabetes can be affected by diabetic neuropathy, opening the doors for diabetic foot to develop.

FutureBridge Report Highlights Evolving Opportunities and Innovation Dynamics in Woundcare

Retrieved on: 
Tuesday, February 27, 2024
Caregiver, Hematoma, Intelligence, Diabetic foot, TPP, Akshi, Abrasion, History, Radiation, Medtech, Patient, Wound, Ulcer, Trauma, Consultant, Pressure, Wound healing

NEW YORK, Feb. 27, 2024 /PRNewswire/ -- FutureBridge, a leading techno-commercial consulting and advisory company, has launched its latest report, "Evolving Opportunities and Innovation Dynamics in Woundcare."

Key Points: 
  • NEW YORK, Feb. 27, 2024 /PRNewswire/ -- FutureBridge, a leading techno-commercial consulting and advisory company, has launched its latest report, "Evolving Opportunities and Innovation Dynamics in Woundcare."
  • The comprehensive wound care report highlights these challenges, exploring critical areas like infection prevention, delayed wound healing, and compromised tissue composition.
  • "AI/ML algorithms-based products, smart wearable dressings, novel personalized biological therapies and collaborative innovation are set to disrupt the woundcare space.
  • FutureBridge invites you to explore the full report to gain profound insights into the future of wound care.

RION Announces Initiation of Phase 2A Clinical Study for Purified Exosome Product™ (PEP™) in Diabetic Foot Ulcers

Retrieved on: 
Tuesday, January 30, 2024
Health, Diabetes, Clinical Trials, Research, Science, Biotechnology, Multimedia, DFU, Amputation, Regenerative medicine, Mayo Clinic, Diabetic foot, Patient, Safety, Exosome, Biologics license application, Ulcer, BLA, Pharmaceutical industry

RION, a clinical-stage regenerative medicine company, at the forefront of the exosome therapeutic revolution, has officially commenced a Phase 2A study aimed at assessing the efficacy and safety of its exclusive exosome regenerative therapeutic, known as Purified Exosome Product™ (PEP™), for the management of Diabetic Foot Ulcers (DFU).

Key Points: 
  • RION, a clinical-stage regenerative medicine company, at the forefront of the exosome therapeutic revolution, has officially commenced a Phase 2A study aimed at assessing the efficacy and safety of its exclusive exosome regenerative therapeutic, known as Purified Exosome Product™ (PEP™), for the management of Diabetic Foot Ulcers (DFU).
  • (Photo: Business Wire)
    Diabetic Foot Ulcers affect approximately 18.6 million people worldwide each year1 and are associated with increasing rates of amputation and death​​.
  • Building on the success of the Phase 1B study conducted at Mayo Clinic, RION's Phase 2A trial represents a significant step forward in the development of a regenerative biologic for Diabetic Foot Ulcers.
  • Not only will this study address a critical unmet need in chronic wound care, but it’s a pivotal moment for RION.

DnaNudge secures FDA approval to deploy a Multiplex PCR platform for diagnosing four-in-one respiratory pathogens in Ghana

Retrieved on: 
Thursday, December 14, 2023
Health, FDA, Medical Devices, Infectious Diseases, Genetics, COVID-19, Biotechnology, Diabetic foot infection, FRS, DnaNudge, Vertically transmitted infection, Research, Urinary tract infection, DNA, RSV, Diabetic foot, Respiratory syncytial virus, Laureate, The Lancet, Clinical trial, Genomics, PCR, University, Medicine, Infection, Biomedicine, City, Medical research, University of Ghana, Imperial College London, RT, Partnership, RNA, Doctor of Philosophy, Quad, AI, SARS, Biomedical engineering, Life, TB, COVID, Vaccine, Medical device, Pharmaceutical industry

The lab-free, highly multiplexed sample-to-result test offers the capabilities of lab-based PCR diagnostics.

Key Points: 
  • The lab-free, highly multiplexed sample-to-result test offers the capabilities of lab-based PCR diagnostics.
  • Unlike the majority of other nucleic acid point-of-care tests based on isothermal amplification methods, the DnaNudge technology uses gold standard RT-PCR.
  • Testing samples can be collected via nasopharyngeal, nasal only or combined nose and throat swabs.
  • The unique lab-free nature of the DnaNudge system means that the test is ideal for use by healthcare professionals in any setting, including urban and rural environments.

BREAKTHROUGH IN DIGITAL HEALTH: WITHINGS HEALTH SOLUTIONS LAUNCHES BODY PRO 2, REVOLUTIONIZING THE DETECTION OF EARLY DIABETES COMPLICATIONS WITH THE NEXT-GEN CELLULAR SCALE

Retrieved on: 
Tuesday, November 14, 2023
Motivation, ESC, Research, Activator (genetics), Diabetic foot, Risk, Body, Patient, Weather, Nature, Withings, Ulcer, Type 2 diabetes, Electrochemical skin conductance, Forecasting, Body composition, DPN, LCD, Biomarker, Diabetes, Pharmaceutical industry, Mobile phone, Medical device

BOSTON, Nov. 14, 2023 /PRNewswire/ -- Today, on World Diabetes Day, Withings Health Solutions provides a leap forward for the digital health industry with the launch of Body Pro 2, a revolutionary device redefining the nature and use of cellular-connected smart scales. Body Pro 2 is the result of years of research and development, consultation with hundreds of digital health partners and clinicians, and embodies Withings' vision that digital health needs to be a better experience for all stakeholders. It combines habit-forming user features with a pioneering modular approach to manage chronic conditions within one versatile device. Its core capabilities allow care teams to capture advanced health metrics such as weight and body composition while additional and optional health modules unlock the ability to track advanced and clinically validated biomarkers typically only available in a professional setting.  

Key Points: 
  • Prevention of type 2 diabetes and diabetes-related complications is the focus of the final year of the World Diabetes Day 2021-23 theme, Access to Diabetes Care.
  • Body Pro 2's first module is prescription-only (Rx) and aims to improve the way patients with diabetes are taken care of.
  • With this module care teams can monitor one of the biggest challenges in diabetes, diabetic foot health, which is often overlooked.
  • 1
    With Body Pro 2, Withings Health Solutions reinforces its value proposition to the digital health industry.

NantNudge and DnaNudge Launch a Revolutionary Genomic Handheld Device, with First-Of-Kind Point-Of-Decision, Lab in Cartridge PCR Test

Retrieved on: 
Monday, November 6, 2023
Medical Devices, Health, Infectious Diseases, Health Technology, COVID-19, Biotechnology, RSV, Nanotechnology, NantWorks, RT, Food, SARS-CoV-2, Life, Imperial College London, Skin care, TB, PCR, Infection, Diabetic foot, Engineering, The Brothers Flub, Genomics, Medicine, Biology, DnaNudge, Diet, Cancer, Tuberculosis, Vertically transmitted infection, Inspiration, Medical device, Vaccine, Management

NantNudge will provide rapid, lab-free point-of-decision diagnostics to a broader audience across the globe, including Central, South, and North America and Africa, at an accelerated rate.

Key Points: 
  • NantNudge will provide rapid, lab-free point-of-decision diagnostics to a broader audience across the globe, including Central, South, and North America and Africa, at an accelerated rate.
  • The company is initiating a soft launch of its revolutionary device, the NantBeam, a wearable camera, activity monitor, and barcode scanner at the Inspirational Women’s Forum in Los Angeles on November 7, 2023 .
  • NantNudge will release its "Quad" test this year, following regulatory approval, which allows for quick detection of SARS-CoV-2, FluA, FluB, and RSV using a single cartridge.
  • We are hugely excited to be working together to create this future through fast, affordable and accessible testing."

PHAXIAM Provides Business and Financial Update For the First Half of 2023

Retrieved on: 
Thursday, September 21, 2023
DFU, Hip, Infection, IST, S. aureus, Bank statement, Fungal infection, Cutis marmorata telangiectatica congenita, Escherichia coli, Authorization, Financial statement, Staphylococcus, Trial of the century, Klebsiella pneumoniae, Pseudomonas aeruginosa, Diabetic foot ulcer, Patient, VAP, Risk, AAC, AMF, POC, Therapy, System, Diabetic foot, ANSM, Antibiotics, Pharmaceutical industry, Vaccine, Urinary tract infection, Lysin, Bloodstream infections

The company is awaiting a second AAC regulatory validation for PJI patients, associated with P. aeruginosa resistance from the ANSM.

Key Points: 
  • The company is awaiting a second AAC regulatory validation for PJI patients, associated with P. aeruginosa resistance from the ANSM.
  • On September 19, 2023, the company announced the extension of its portfolio to Klebsiella pneumoniae, a new resistant aggressive bacterial target.
  • Key financial figures for the first half of 2023 compared with the same period of the previous year are summarized below.
  • In the context of the Erytech-Pherecydes merger, PHAXIAM’s consolidated financial statements in IFRS standards include ex-Pherecydes financial results as of the date of the merger, i.e.

Kane Biotech Announces Second Quarter 2023 Financial Results

Retrieved on: 
Tuesday, August 29, 2023
Regulation of tobacco by the U.S. Food and Drug Administration, Health, Unit, Leg, Financial statement, Sale, Certification, US, KNE, Diabetic foot, SEDAR, Ulcer, FDA, US FDA, Food, Music, Cryptocurrency, Pharmaceutical industry, STEM

WINNIPEG, Manitoba, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”) today announced its second quarter 2023 financial results.

Key Points: 
  • 68% Increase in Product and Services Revenue; 74% Increase in Royalties Revenue
    WINNIPEG, Manitoba, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”) today announced its second quarter 2023 financial results.
  • Gross profit for the second quarter of 2023 was $330,505, a decrease of 48% compared to $639,215 for the quarter ended June 30, 2022.
  • Loss for the second quarter of 2023 was ($967,905), an increase of 22% compared to ($794,595) for the quarter ended June 30, 2022.
  • Detailed financial information about Kane Biotech can be found in its June 30, 2023 Financial Statements and Management Discussion and Analysis on SEDAR and the Company’s website.